MetLife Investment Management’s Insmed INSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.27M Sell
11,926
-364
-3% -$44.1K 0.01% 1399
2026
Q1
$2.01M Sell
12,290
-601
-5% -$92.4K 0.01% 1057
2025
Q4
$2.24M Buy
12,891
+1,518
+13% +$277K 0.01% 1027
2025
Q3
$1.64M Buy
11,373
+784
+7% +$96K 0.01% 1197
2025
Q2
$1.07M Sell
10,589
-89,621
-89% -$6.85M 0.01% 1273
2025
Q1
$7.65M Sell
100,210
-3,219
-3% -$246K 0.04% 429
2024
Q4
$7.14M Buy
103,429
+13,807
+15% +$994K 0.04% 382
2024
Q3
$6.54M Buy
89,622
+52
+0.1% +$3.84K 0.04% 395
2024
Q2
$6M Buy
89,570
+18,545
+26% +$719K 0.04% 408
2024
Q1
$1.93M Sell
71,025
-1,423
-2% -$39.8K 0.01% 967
2023
Q4
$2.25M Buy
72,448
+3,530
+5% +$91.5K 0.02% 906
2023
Q3
$1.74M Hold
68,918
0.01% 964
2023
Q2
$1.45M Sell
68,918
-1,921
-3% -$36.4K 0.01% 1070
2023
Q1
$1.21M Hold
70,839
0.01% 1130
2022
Q4
$1.42M Buy
70,839
+7,955
+13% +$154K 0.01% 1038
2022
Q3
$1.35M Hold
62,884
0.01% 1043
2022
Q2
$1.24M Hold
62,884
0.01% 1103
2022
Q1
$1.48M Buy
62,884
+22,831
+57% +$530K 0.01% 1121
2021
Q4
$1.09M Hold
40,053
0.01% 1091
2021
Q3
$1.1M Buy
40,053
+1,626
+4% +$42.7K 0.01% 1073
2021
Q2
$1.09M Hold
38,427
0.01% 1113
2021
Q1
$1.31M Sell
38,427
-3,396
-8% -$130K 0.01% 1013
2020
Q4
$1.39M Sell
41,823
-2,973
-7% -$109K 0.01% 985
2020
Q3
$1.44M Hold
44,796
0.02% 866
2020
Q2
$1.23M Buy
44,796
+5,212
+13% +$124K 0.01% 944
2020
Q1
$635K Hold
39,584
0.01% 1087
2019
Q4
$945K Hold
39,584
0.01% 1126
2019
Q3
$698K Buy
39,584
+2,568
+7% +$49.6K 0.01% 1242
2019
Q2
$948K Buy
37,016
+3,783
+11% +$105K 0.01% 1131
2019
Q1
$966K Hold
33,233
0.01% 1099
2018
Q4
$436K Hold
33,233
0.01% 1450
2018
Q3
$672K Sell
33,233
-4,419
-12% -$99.8K 0.01% 1345
2018
Q2
$890K Buy
37,652
+4,160
+12% +$107K 0.01% 1068
2018
Q1
$754K Hold
33,492
0.01% 1138
2017
Q4
$1.04M Buy
+33,492
New +$989K 0.01% 1015

Other funds holding INSM

MetLife Investment Management's INSM Position: Q2 2026 in Review

MetLife Investment Management reduced its Insmed (INSM) stake by 3% in Q2 2026, selling an estimated $44.1K and leaving 11,926 shares worth $1.27M. The position accounts for 0.01% of the portfolio, ranked #1399.

MetLife Investment Management first reported a position in INSM in Q4 2017 and has held it in 35 quarters since. The position peaked at $7.65M in Q1 2025. 663 funds tracked by Wall St. Rank hold INSM as of Q2 2026.

  • MetLife Investment Management held 11,926 shares of Insmed worth $1.27M as of Q2 2026.
  • MetLife Investment Management sold 364 Insmed shares in Q2 2026, an estimated $44.1K.
  • Insmed made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1399 holding.
  • MetLife Investment Management first reported a position in Insmed in Q4 2017 and has held it in 35 quarters since.
  • MetLife Investment Management's Insmed position peaked at $7.65M in Q1 2025.
  • 663 funds tracked by Wall St. Rank held Insmed as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.